GlassScriptPhysician profile
Christopher S Reed
NPI 1992237861
$79,639.09
in general payments reported to CMS, 2019-2025
27 companies · $4,361 in 2025
The $4,361 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $27.02 · 2021: $207 · 2022: $415 · 2023: $33K · 2024: $41K · 2025: $4,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $70K · Food and Beverage: $5,491 · Travel and Lodging: $3,038 · Education: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $70,000.00 |
| Food and Beverage | $5,491.11 |
| Travel and Lodging | $3,038.16 |
| Education | $336.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $33,044.64 | 2020-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Abbott Laboratories | $30,559.33 | 2023-2025 | Tacticath Ablation Catheter, Sensor Enabled, Tacticath, Coroflow |
| Medtronic, INC. | $12,494.29 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Linq II |
| Biotronik INC. | $991.66 | 2023-2025 | Acticor 7 Vr-T Dx, Plexa Promri, Selectra |
| Cardiva Medical, INC. | $447.61 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Inari Medical, INC. | $431.93 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Biosense Webster, INC. | $374.59 | 2024-2025 | Carto 3, Soundstar, Na |
| Atricure, INC. | $223.39 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Janssen Pharmaceuticals, INC | $173.38 | 2024 | Xarelto |
| Cvrx, INC. | $143.67 | 2025 | Barostim Neo System |
| Allergan, INC. | $124.83 | 2019 | |
| Terumo Medical Corporation | $122.66 | 2022-2023 | Metacross Otw |
| Novo Nordisk INC | $87.73 | 2023-2025 | Ozempic, Wegovy |
| Heartflow, INC. | $56.15 | 2025 | |
| Pfizer INC. | $55.56 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $43.42 | 2023-2024 | Brilinta |
| Abiomed | $38.53 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.91 | 2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $32.33 | 2023-2024 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $22.14 | 2025 | Uptravi, Opsumit |
| Ferring Pharmaceuticals INC. | $19.64 | 2022 | |
| Lantheus Medical Imaging, INC. | $19.03 | 2021 | |
| Zoll Circulation INC | $17.89 | 2025 | Therox Ds2 Console, Downstream Cartridge, Catheter |
| Chiesi USA, INC. | $13.91 | 2024 | Kengreal, Cleviprex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.82 | 2021 | |
| Cardiovascular Systems INC. | $5.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.